SunGard MDS buys Fame

The move will help SunGard expand its data coverage while allowing Fame’s majority backer Warburg Pincus to spin-off its investment.

The deal marks SunGard MDS’s entry into the field of reference data and historical data, the company having until now concentrated on real-time data, particularly in the US retail equities market.

John Hyde, group chief executive of SunGard MDS, said the company has been looking to get into the reference data business for around a year. "Reference data is a rapidly evolving area, and we thought it was a good time to leverage Fame’s services," Hyde said.

Yet it may cause further confusion in the industry over SunGard MDS’s strategy in the real-time arena. Some industry observers have noted that, although the company has publicly stated its ambitions to move into the real-time institutional space, it does not seem to have made much progress.

A source at the company told RiskNews' sister publication Inside Market Data that SunGard MDS is aggressively going after real-time opportunities. Hyde responded by saying that SunGard MDS is "always looking to grow its business", but declined to comment on the company’s future plans in the reference data business or on other potential acquisition targets.

Fame will be run as an independent division of SunGard MDS, Hyde said. Dale Richards will remain president and chief executive, and there are no plans for layoffs.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Next-generation technologies and the future of trading

At a webinar in association with capital markets technology provider Numerix, panellists discuss the potential for increased adoption of the public cloud to boost investment performance, its impact on risk management and overcoming barriers to…

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here